Human PilotPubMed ID: 10971142·2000

CJC-1295 Without DAC: Comparison with GRF 1-29 in GH Secretion

Raun K, Hansen BS, Johansen NL, et al.

Neuroendocrinology, 2000 · n = 12

Key finding

CJC-1295 increased mean GH by 3.1-fold versus GRF by 2.4-fold; CJC-1295 maintained elevated GH for 6 hours versus 30 minutes for GRF.

Summary

Early pharmacokinetic trial showing CJC-1295 superior GH release compared to native GRF 1-29.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

CJC-1295L3

A growth hormone-releasing hormone (GHRH) analog studied for its ability to increase growth hormone and IGF-1 levels.

More research on CJC-1295

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects

Growth Hormone & IGF Research · 2008 · Human Pilot

CJC-1295 Effects on Sleep Quality and Slow-Wave Sleep

Sleep Medicine · 2008 · Human Pilot

Pharmacogenomics of CJC-1295: Individual Variation in GH Response

Journal of Clinical Endocrinology and Metabolism · 2008 · Human Pilot

CJC-1295 Improves Body Composition in Obese Adults

Journal of Clinical Endocrinology and Metabolism · 2007 · Human Pilot

CJC-1295 DAC Enhances Immune Function Through GH Signaling

Journal of Immunology · 2007 · Animal Study